RetinaCME
EXPERT INTERVIEWCMEABO MOC

Surgical Delivery Systems That Extend Treatment Intervals for nAMD and DME: Closer Than You Think!

Author(s)/Faculty: Margaret A. Chang, MD, MS; Jordan M. Graff, MD, FACS, FABO
Release Date: 11/19/2021Expiration Date: 11/18/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Treatment burden and loss of patient adherence due to dosing schedules remain an unmet need in the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Even though current treatment protocols have been refined to extend the time between treatment intervals, many patients are unable to move beyond a 4-to-8-week dosing schedule. Ongoing clinical studies are evaluating gene therapy and sustained delivery devices as potential options to extend treatment intervals while maintaining visual acuity. To achieve optimal efficacy outcomes and safety of these new extend treatment modalities, unique surgical approaches must be utilized. In this CME activity, experts in the field assess emerging surgical delivery systems that have the potential to extend the interval between treatments for patients with DME and nAMD, as well as review novel surgical techniques and procedures to minimize ocular adverse events.